VitalStim, LLC (VitalStim), ESD, LLC (ESD), DJO, LLC ((DJO), and Empi, Inc. (Empi) filed suit on December 3, 2012, against eSwallow USA, LLC (eSwallow) asserting infringement of four patents: U.S. Patent 5,725,564 (the ‘564 Patent), U.S. Patent 5,987,359 (the ‘359 Patent), U.S. Patent 6,104,958 (the ‘958 Patent), and U.S. Patent 7,280,873 (the ‘873 Patent) (collectively, the Dysphagia Patents). The plaintiffs allege that they, among themselves, either own or exclusively license the patents, or are sublicensed by the exclusive licensee.
VitalStim alleges its own status as an innovator in the development of safe and effective treatments for patients suffering with difficulty swallowing or dysphagia. The VitalStim® Therapy System is presented on its website as follows:
The complaint alleges that the managing principal of eSwallow was a former distributor of the VitalStim® Therapy System. In additional to the implication of knowledge through that former relationship, VitalStim alleges that the User Manuals for VitalStim products covered by the Dysphagia Patents have been continuously marked with three of the four patents since 2005 in compliance with 35 USC § 287.
VitalStim alleges that eSwallow has infringed the Dysphagia Patents with “an electrical pharyngeal neuromuscular stimulator, identified as the eSwallow Dysphagia Therapy Unit Models 9950/9960. The following image of a Stimulation Unit appears on the eSwallow website:
The case is VitalStim, LLC, et. al v. eSwallow USA, LLC., No. 1:12-cv-4163-JOF, filed 12/03/12 in the U.S. District Court for the Northern District of Georgia, Atlanta Division, assigned to U.S. District Judge J. Owen Forrester.